2025
Risk of Bacterial Infections in Febrile Infants 61 to 90 Days Old With Respiratory Viruses.
Aronson P, Mahajan P, Nielsen B, Olsen C, Meeks H, Grundmeier R, Kuppermann N. Risk of Bacterial Infections in Febrile Infants 61 to 90 Days Old With Respiratory Viruses. 2025, 156 PMID: 40506050, DOI: 10.1542/peds.2025-070617.Peer-Reviewed Original ResearchConceptsPrevalence of urinary tract infectionUrinary tract infectionPediatric Emergency Care Applied Research NetworkRespiratory viral testingRespiratory viral infectionsFebrile infantsBacterial meningitisRespiratory virusesSARS-CoV-2Viral testingViral infectionSARS-CoV-2-positive infantsBacterial infectionsRisk of bacterial infectionPrevalence of bacteremiaPrevalence of bacterial infectionRespiratory syncytial virusBlood culturesTract infectionsPositive infantsSyncytial virusNegative infantsBacteremiaMeningitisInfantsACR Appropriateness Criteria® Acute Respiratory Illness in Immunocompetent Patients: 2024 Update
Imaging P, Batra K, Walker C, Little B, Bang T, Bartel T, Brixey A, Christensen J, Cox C, Hanak M, Khurana S, Madan R, Merchant N, Moore W, Pandya S, Sanchez L, Shroff G, Zagurovskaya M, Chung J. ACR Appropriateness Criteria® Acute Respiratory Illness in Immunocompetent Patients: 2024 Update. Journal Of The American College Of Radiology 2025, 22: s14-s35. PMID: 40409874, DOI: 10.1016/j.jacr.2025.02.014.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseEvidence-Based MedicineHumansImmunocompetenceRespiratory Tract InfectionsSocieties, MedicalUnited StatesConceptsAcute respiratory illnessRespiratory illnessManagement of acute respiratory illnessesAmerican College of Radiology Appropriateness CriteriaRAND/UCLA Appropriateness Method User ManualSelf-limiting viral infectionEvidence-based guidelinesEstablished methodology principlesImmunocompetent adult patientsChronic obstructive pulmonary disease exacerbationsAppropriateness of imagingPublic health issuePeer-reviewed journalsFollow-up imagingMultidisciplinary expert panelSuspected pneumonia casesPeer-reviewed literatureGuideline developmentRecommendations AssessmentImmunocompetent patientsOccult malignancyHealth issuesExpert panelAdult patientsAppropriateness CriteriaDecreased T helper 1 cell function underlies recurrent sinopulmonary infections in the 17q12 deletion syndrome
Shin J, Shin H, Gutierrez A, Yoo N, Par-Young J, Osmani L, Shin M, Sanchez-Lara P, Bucala R, Soffer G, Kang I. Decreased T helper 1 cell function underlies recurrent sinopulmonary infections in the 17q12 deletion syndrome. EBioMedicine 2025, 112: 105578. PMID: 39891996, PMCID: PMC11840234, DOI: 10.1016/j.ebiom.2025.105578.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultChildChild, PreschoolChromosome DeletionChromosomes, Human, Pair 17CytokinesFemaleHumansMaleRespiratory Tract InfectionsT-Box Domain ProteinsTh1 CellsYoung AdultConceptsCD4<sup>+</sup> T cellsRecurrent sinopulmonary infectionsT cell functionRNA-seq analysisT cellsHealthy controlsSinopulmonary infectionsRNA-seqT-betIFN-gFrequency of CD4<sup>+</sup> T cellsCD4<sup>+</sup> T cell functionTh1 transcription factor T-betDeletion syndromeFlow cytometryCompared to age-matched healthy controlsTranscription factor T-betDecreased T-betUrinary tract abnormalitiesAge-matched healthy controlsMultiplex assayDownstream effector cytokinesEffector cytokinesRecurrent infectionsTh17 cytokines
2024
Antecedent and persistent symptoms in COVID-19 and other respiratory illnesses: Insights from prospectively collected data in the BRACE trial
ald E, Pittet L, Barry S, Bonten M, Campbell J, Croda J, Croda M, Dalcolmo M, Davidson A, de Almeida e Val F, dos Santos G, Gardiner K, Gell G, Gwee A, Krastev A, Lacerda M, Lucas M, Lynn D, Manning L, McPhate N, Perrett K, Post J, Prat-Aymerich C, Quinn L, Richmond P, Wood N, Messina N, Curtis N, Group T. Antecedent and persistent symptoms in COVID-19 and other respiratory illnesses: Insights from prospectively collected data in the BRACE trial. Journal Of Infection 2024, 89: 106267. PMID: 39245151, PMCID: PMC11489119, DOI: 10.1016/j.jinf.2024.106267.Peer-Reviewed Original ResearchMeSH KeywordsAdultCOVID-19FemaleHealth PersonnelHumansMaleMiddle AgedPost-Acute COVID-19 SyndromeProspective StudiesRespiratory Tract InfectionsSARS-CoV-2Severity of Illness IndexConceptsBraced trialsChronic respiratory diseasesHealthcare workersPre-existing symptomsRisk of PaCMulticentre randomised controlled trialNon-COVID-19Non-COVID-19 respiratory illnessesRandomised controlled trialsRespiratory illnessNon-COVID-19 illnessesSymptom patternsLonger-lasting symptomsProportion of COVID-19 casesRespiratory diseaseIllness episodesWHO definitionCOVID-19Compare symptomsControlled trialsRespiratory illness episodesSymptom dataPersistence of symptomsIllnessIncreased riskPostinfectious Pulmonary Complications: Establishing Research Priorities to Advance the Field: An Official American Thoracic Society Workshop Report.
Auld S, Sheshadri A, Alexander-Brett J, Aschner Y, Barczak A, Basil M, Cohen K, Dela Cruz C, McGroder C, Restrepo M, Ridge K, Schnapp L, Traber K, Wunderink R, Zhang D, Ziady A, Attia E, Carter J, Chalmers J, Crothers K, Feldman C, Jones B, Kaminski N, Keane J, Lewinsohn D, Metersky M, Mizgerd J, Morris A, Ramirez J, Samarasinghe A, Staitieh B, Stek C, Sun J, Evans S. Postinfectious Pulmonary Complications: Establishing Research Priorities to Advance the Field: An Official American Thoracic Society Workshop Report. Annals Of The American Thoracic Society 2024, 21: 1219-1237. PMID: 39051991, DOI: 10.1513/annalsats.202406-651st.Peer-Reviewed Original ResearchMeSH KeywordsBiomedical ResearchCOVID-19HumansLung DiseasesRespiratory Tract InfectionsSARS-CoV-2Societies, MedicalUnited StatesConceptsPulmonary infectionTreatment of pulmonary infectionsLower respiratory tract infectionsLong-term morbidityRespiratory tract infectionsShort-term outcomesAberrant host responseBurden of morbidityReview potential mechanismsPulmonary complicationsTract infectionsPulmonary pathogensSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Causative pathogenRespiratory syndrome coronavirus 2Therapeutic strategiesSyndrome coronavirus 2Host responseInfectionMorbidityPotential mechanismsCoronavirus 2Intranasal neomycin evokes broad-spectrum antiviral immunity in the upper respiratory tract
Mao T, Kim J, Peña-Hernández M, Valle G, Moriyama M, Luyten S, Ott I, Gomez-Calvo M, Gehlhausen J, Baker E, Israelow B, Slade M, Sharma L, Liu W, Ryu C, Korde A, Lee C, Monteiro V, Lucas C, Dong H, Yang Y, Initiative Y, Gopinath S, Wilen C, Palm N, Dela Cruz C, Iwasaki A, Vogels C, Hahn A, Chen N, Breban M, Koch T, Chaguza C, Tikhonova I, Castaldi C, Mane S, De Kumar B, Ferguson D, Kerantzas N, Peaper D, Landry M, Schulz W, Grubaugh N. Intranasal neomycin evokes broad-spectrum antiviral immunity in the upper respiratory tract. Proceedings Of The National Academy Of Sciences Of The United States Of America 2024, 121: e2319566121. PMID: 38648490, PMCID: PMC11067057, DOI: 10.1073/pnas.2319566121.Peer-Reviewed Original ResearchConceptsInterferon-stimulated genesRespiratory infectionsStrains of influenza A virusTreatment of respiratory viral infectionsRespiratory virus infectionsInfluenza A virusMouse model of COVID-19Respiratory viral infectionsNeomycin treatmentExpression of interferon-stimulated genesUpper respiratory infectionInterferon-stimulated gene expressionLower respiratory infectionsBroad spectrum of diseasesAdministration of neomycinRespiratory viral diseasesDisease to patientsUpper respiratory tractIntranasal deliveryCongenic miceIntranasal applicationNasal mucosaSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2A virusNovel Approaches to Multidrug-Resistant Infections in Cystic Fibrosis
Murray T, Stanley G, Koff J. Novel Approaches to Multidrug-Resistant Infections in Cystic Fibrosis. Infectious Disease Clinics Of North America 2024, 38: 149-162. PMID: 38280761, DOI: 10.1016/j.idc.2023.12.002.Peer-Reviewed Original ResearchMeSH KeywordsAnti-Bacterial AgentsAnti-Infective AgentsCystic FibrosisHumansMethicillin-Resistant Staphylococcus aureusRespiratory Tract InfectionsStenotrophomonas maltophiliaConceptsMultidrug-resistant organismsCystic fibrosis transmembrane conductance regulatorCystic fibrosisBeta-lactam/beta-lactamase combinationDevelopment of inhaled formulationsMethicillin-resistant Staphylococcus aureusTherapeutic approachesMultidrug-resistant organism infectionSystemic adverse eventsMultidrug-resistant infectionsTransmembrane conductance regulatorRespiratory tract infectionsCystic fibrosis patientsGram-negative organismsInnovative therapeutic approachesPulmonary infectionTract infectionsConductance regulatorBurkholderia sp.Multidrug resistanceAdverse eventsTreatment optionsAntibiotic resistanceFibrosis patientsOptimal dose
2023
Molecular characterisation of human adenoviruses associated with respiratory infections in Uganda
Ukuli Q, Erima B, Mubiru A, Atim G, Tugume T, Kibuuka H, Mworozi E, Ducatez M, Wabwire-Mangen F, Byarugaba D. Molecular characterisation of human adenoviruses associated with respiratory infections in Uganda. BMC Infectious Diseases 2023, 23: 435. PMID: 37370005, PMCID: PMC10294467, DOI: 10.1186/s12879-023-08403-9.Peer-Reviewed Original ResearchMeSH KeywordsAdenovirus Infections, HumanAdenoviruses, HumanAdultChildGenotypeHumansInfantPhylogenyRespiratory Tract InfectionsSequence Analysis, DNAUgandaConceptsPolymerase chain reactionSpecies of human adenovirusHuman adenovirusDiverse group of virusesMultiple genetic variantsInfluenza-like illnessAdenovirus-vectored vaccineGroup of virusesGenome sequenceGenetic diversityAdenovirus-positiveHAdV infectionGenomic characterizationSequenced isolatesSpecies HAdV-BGenetic variantsRespiratory infectionsChildren aged 5Hexon geneNasopharyngeal samplesGenotype B3Molecular characterisationTertiary hospitalUgandan populationCell linesThe COVID-19 pandemic as an opportunity for unravelling the causative association between respiratory viruses and pneumococcus-associated disease in young children: a prospective study
Dagan R, van der Beek B, Ben-Shimol S, Greenberg D, Shemer-Avni Y, Weinberger D, Danino D. The COVID-19 pandemic as an opportunity for unravelling the causative association between respiratory viruses and pneumococcus-associated disease in young children: a prospective study. EBioMedicine 2023, 90: 104493. PMID: 36857965, PMCID: PMC9970381, DOI: 10.1016/j.ebiom.2023.104493.Peer-Reviewed Original ResearchConceptsCommunity-acquired alveolar pneumoniaLower respiratory infectionsRespiratory syncytial virusInvasive pneumococcal diseaseHuman metapneumovirusDisease endpointsPneumococcal diseaseRespiratory virusesProspective studyNasopharyngeal pneumococcal carriagePneumococcal bacteremic pneumoniaProspective surveillance programRespiratory virus activityCommon respiratory virusesPneumococcal carriage prevalenceBurden of diseaseDifferent clinical endpointsYoung childrenCOVID-19 pandemicProportion of testsAlveolar pneumoniaBacteremic pneumoniaPneumococcal carriageRespiratory infectionsCarriage prevalenceVirology under the Microscope—a Call for Rational Discourse
Goodrum F, Lowen A, Lakdawala S, Alwine J, Casadevall A, Imperiale M, Atwood W, Avgousti D, Baines J, Banfield B, Banks L, Bhaduri-McIntosh S, Bhattacharya D, Blanco-Melo D, Bloom D, Boon A, Boulant S, Brandt C, Broadbent A, Brooke C, Cameron C, Campos S, Caposio P, Chan G, Cliffe A, Coffin J, Collins K, Damania B, Daugherty M, Debbink K, DeCaprio J, Dermody T, Dikeakos J, DiMaio D, Dinglasan R, Duprex W, Dutch R, Elde N, Emerman M, Enquist L, Fane B, Fernandez-Sesma A, Flenniken M, Frappier L, Frieman M, Frueh K, Gack M, Gaglia M, Gallagher T, Galloway D, García-Sastre A, Geballe A, Glaunsinger B, Goff S, Greninger A, Hancock M, Harris E, Heaton N, Heise M, Heldwein E, Hogue B, Horner S, Hutchinson E, Hyser J, Jackson W, Kalejta R, Kamil J, Karst S, Kirchhoff F, Knipe D, Kowalik T, Lagunoff M, Laimins L, Langlois R, Lauring A, Lee B, Leib D, Liu S, Longnecker R, Lopez C, Luftig M, Lund J, Manicassamy B, McFadden G, McIntosh M, Mehle A, Miller W, Mohr I, Moody C, Moorman N, Moscona A, Mounce B, Munger J, Münger K, Murphy E, Naghavi M, Nelson J, Neufeldt C, Nikolich J, O'Connor C, Ono A, Orenstein W, Ornelles D, Ou J, Parker J, Parrish C, Pekosz A, Pellett P, Pfeiffer J, Plemper R, Polyak S, Purdy J, Pyeon D, Quinones-Mateu M, Renne R, Rice C, Schoggins J, Roller R, Russell C, Sandri-Goldin R, Sapp M, Schang L, Schmid S, Schultz-Cherry S, Semler B, Shenk T, Silvestri G, Simon V, Smith G, Smith J, Spindler K, Stanifer M, Subbarao K, Sundquist W, Suthar M, Sutton T, Tai A, Tarakanova V, tenOever B, Tibbetts S, Tompkins S, Toth Z, van Doorslaer K, Vignuzzi M, Wallace N, Walsh D, Weekes M, Weinberg J, Weitzman M, Weller S, Whelan S, White E, Williams B, Wobus C, Wong S, Yurochko A. Virology under the Microscope—a Call for Rational Discourse. MBio 2023, 14: e00188-23. PMID: 36700642, PMCID: PMC9973315, DOI: 10.1128/mbio.00188-23.Peer-Reviewed Original ResearchConceptsOrigin of SARS-CoV-2Evidence-based discourseRational discourseVirology researchGain-of-function approachesVirus-related researchPolicy makersField of virologyLegitimate questionsHuman pathogensDiscourseVocal groupRegulatory structureSARS-CoV-2United StatesPublic concernPublic confusionGroup of individualsNovel DNMT3B Mutation in a Patient with Immunodeficiency, Centromeric Instability, and Facial Anomalies (ICF) Syndrome and a Bronchopulmonary Collateral Artery
Esmaeilzadeh H, Rezaei N, Aminorroaya A, Rayzan E, Shahkarami S, Seyedpour S, Zoghi S, Aryan Z, Somekh I, Rohlfs M, Klein C. Novel DNMT3B Mutation in a Patient with Immunodeficiency, Centromeric Instability, and Facial Anomalies (ICF) Syndrome and a Bronchopulmonary Collateral Artery. Endocrine Metabolic & Immune Disorders - Drug Targets 2023, 23: 410-415. PMID: 35996251, DOI: 10.2174/1871530322666220822141722.Peer-Reviewed Original ResearchConceptsRecurrent respiratory infectionsFacial anomaliesDNMT3B mutationsRecurrent infectionsCollateral arteriesFamily historyRespiratory infectionsHistory of recurrent respiratory infectionsAssociated with recurrent infectionsCentromeric instabilityFamily history of consanguinityRare autosomal recessive disorderRecurrent episodes of pneumoniaMonthly intravenous immunoglobulinProphylactic trimethoprim-sulfamethoxazolePrimary immune deficiencyBone marrow studyLow-set earsPatent ductus arteriosusEvaluation of neutropeniaEpisodes of pneumoniaHistory of consanguinityMild facial anomaliesAutosomal recessive disorderSystolic cardiac murmur
2022
Novel Approaches to Multidrug-Resistant Infections in Cystic Fibrosis
Murray T, Stanley G, Koff J. Novel Approaches to Multidrug-Resistant Infections in Cystic Fibrosis. Clinics In Chest Medicine 2022, 43: 667-676. PMID: 36344073, DOI: 10.1016/j.ccm.2022.06.008.Peer-Reviewed Original ResearchMeSH KeywordsAnti-Bacterial AgentsCystic FibrosisHumansMethicillin-Resistant Staphylococcus aureusPseudomonas aeruginosaPseudomonas InfectionsRespiratory Tract InfectionsStenotrophomonas maltophiliaConceptsMultidrug-resistant organismsCystic fibrosisTherapeutic approachesNontuberculous mycobacteriaCystic fibrosis transmembrane conductance regulator (CFTR) dysfunctionSystemic adverse eventsRespiratory tract infectionsMethicillin-resistant Staphylococcus aureusAdditional clinical trialsNew treatment optionsPharmacokinetics/pharmacodynamicsInnovative therapeutic approachesMultidrug-resistant infectionsMDRO infectionAdverse eventsPulmonary infectionTract infectionsOptimal dosingTreatment optionsClinical trialsNew therapiesNegative organismsInfectionAntibiotic resistancePatientsVariation in bacterial pneumonia diagnoses and outcomes among children hospitalized with lower respiratory tract infections
Cotter J, Hall M, Shah S, Molloy M, Markham J, Aronson P, Stephens J, Steiner M, McCoy E, Collins M, Tchou M. Variation in bacterial pneumonia diagnoses and outcomes among children hospitalized with lower respiratory tract infections. Journal Of Hospital Medicine 2022, 17: 872-879. PMID: 35946482, PMCID: PMC11366396, DOI: 10.1002/jhm.12940.Peer-Reviewed Original ResearchMeSH KeywordsAnti-Bacterial AgentsChildCommunity-Acquired InfectionsCross-Sectional StudiesHospitals, PediatricHumansPneumoniaPneumonia, BacterialRespiratory Tract InfectionsConceptsBacterial community-acquired pneumoniaLower respiratory tract infectionsCommunity-acquired pneumoniaRespiratory tract infectionsProportion of childrenTract infectionsDiagnosis groupsMulticenter cross-sectional studyLength of stayCross-sectional studyCause revisitsClinical outcomesBlood testsChildren's HospitalViral causeCaP diagnosisChest radiographsMAIN OUTCOMEMultivariable regressionPneumonia diagnosisHospitalDiagnosisOutcomesReadmissionSignificant differencesThe protocol of improving safe antibiotic prescribing in telehealth: A randomized trial
McCabe B, Linder J, Doctor J, Friedberg M, Fox C, Goldstein N, Knight T, Kaiser K, Tibbels J, Haenchen S, Persell S, Warberg R, Meeker D. The protocol of improving safe antibiotic prescribing in telehealth: A randomized trial. Contemporary Clinical Trials 2022, 119: 106834. PMID: 35724841, DOI: 10.1016/j.cct.2022.106834.Peer-Reviewed Original ResearchMeSH KeywordsAnti-Bacterial AgentsElectronic Health RecordsHumansInappropriate PrescribingPractice Patterns, Physicians'Randomized Controlled Trials as TopicRespiratory Tract InfectionsTelemedicineConceptsAcute respiratory infectionsInappropriate antibiotic prescribingAntibiotic prescribing ratesAntibiotic prescribingPrescribing ratesRandomized quality improvement trialAntibiotic stewardship interventionsInappropriate antibiotic prescriptionsUrgent care visitsPrevious randomized trialsPrimary care clinicsQuality improvement trialEffective antibiotic useElectronic health recordsARI visitsInappropriate prescribingAntibiotic prescriptionsCare visitsSecondary outcomesPrimary outcomeRespiratory infectionsCare clinicsRandomized trialsStewardship interventionsAntibiotic useRapid expansion and extinction of antibiotic resistance mutations during treatment of acute bacterial respiratory infections
Chung H, Merakou C, Schaefers M, Flett K, Martini S, Lu R, Blumenthal J, Webster S, Cross A, Al Ahmar R, Halpin E, Anderson M, Moore N, Snesrud E, Yu H, Goldberg J, O’Toole G, McGann P, Stam J, Hinkle M, McAdam A, Kishony R, Priebe G. Rapid expansion and extinction of antibiotic resistance mutations during treatment of acute bacterial respiratory infections. Nature Communications 2022, 13: 1231. PMID: 35264582, PMCID: PMC8907320, DOI: 10.1038/s41467-022-28188-w.Peer-Reviewed Original ResearchConceptsAntibiotic resistance mutationsResistance mutationsLong-read sequencingEvolution of antibiotic resistanceSputum samplesRespiratory infectionsCulture-based methodsLow-frequency resistance mutationsColonization bottlenecksEarly stages of infectionDays of therapyAcute bacterial infectionBacterial respiratory infectionsMechanically ventilated patientsGenomic surveillanceResistance phenotypeStages of infectionAntibiotic resistanceIn vivo frequencyAntibiotic therapyAntibiotic changeMutationsAntibiotic switchTherapy choiceIndividual patients
2021
Risk of lower respiratory tract infections: a genome-wide association study with Mendelian randomization analysis in three independent European populations
Flatby HM, Rasheed H, Ravi A, Thomas LF, Liyanarachi KV, Afset JE, DeWan AT, Brumpton BM, Hveem K, Åsvold BO, Simonsen GS, Furberg AS, Damås JK, Solligård E, Rogne T. Risk of lower respiratory tract infections: a genome-wide association study with Mendelian randomization analysis in three independent European populations. Clinical Microbiology And Infection 2021, 28: 732.e1-732.e7. PMID: 34763054, DOI: 10.1016/j.cmi.2021.11.004.Peer-Reviewed Original ResearchMeSH KeywordsBody Mass IndexGenetic Predisposition to DiseaseGenome-Wide Association StudyHumansMendelian Randomization AnalysisRespiratory Tract InfectionsConceptsLower respiratory tract infectionsRespiratory tract infectionsMendelian randomization analysisTract infectionsRisk factorsRisk of LRTICardiometabolic risk factorsSystolic blood pressureTrøndelag Health StudyPrevalence of smokingRandomization analysisBody mass indexCause of morbidityPotential risk factorsBlood pressureMass indexSuch hospitalizationsDisease burdenProtective effectHealth StudyIndependent European populationsLifetime smokingGenome-wide association studiesGenetic susceptibilitySmokingAlcohol Use and the Risk of Communicable Diseases
Morojele NK, Shenoi SV, Shuper PA, Braithwaite RS, Rehm J. Alcohol Use and the Risk of Communicable Diseases. Nutrients 2021, 13: 3317. PMID: 34684318, PMCID: PMC8540096, DOI: 10.3390/nu13103317.Peer-Reviewed Original ResearchMeSH KeywordsAlcoholismCommunicable DiseasesComorbidityCOVID-19Global Burden of DiseaseHIV InfectionsHumansRespiratory Tract InfectionsRiskSARS-CoV-2TuberculosisConceptsCommunicable diseasesTreatment outcomesSevere acute respiratory syndrome coronavirus 2Respiratory infection/pneumoniaAcute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2Alcohol useDisability-adjusted life yearsSyndrome coronavirus 2Poor treatment outcomesCOVID-19 infectionAlcohol use disorderGlobal health concernIndividual-level interventionsDifferent communicable diseasesTB deathsImmunodeficiency virusCoronavirus 2Severe illnessUse disordersPneumoniaHeavy drinkersLife yearsHIV researchTuberculosisOutbreak of Acute Respiratory Illness Associated With Human Adenovirus Type 4 at the United States Coast Guard Academy, 2019
Chu VT, Simon E, Lu X, Rockwell P, Abedi GR, Gardner C, Kujawski SA, Schneider E, Gentile M, Ramsey LA, Liu R, Jones S, Janik C, Siniscalchi A, Landry ML, Christopher J, Lindstrom S, Steiner S, Thomas D, Gerber SI, Biggs HM. Outbreak of Acute Respiratory Illness Associated With Human Adenovirus Type 4 at the United States Coast Guard Academy, 2019. The Journal Of Infectious Diseases 2021, 225: 55-64. PMID: 34139752, DOI: 10.1093/infdis/jiab322.Peer-Reviewed Original ResearchConceptsMedical recordsRespiratory outbreaksPolymerase chain reaction testingReal-time polymerase chain reaction testingNew-onset coughPositive patient samplesAdenovirus type 4Cadet trainingRoutine vaccinationSore throatAdenovirus vaccineIllness AssociatedHuman adenovirus type 4Respiratory specimensUnderlying conditionDuty restrictionsReaction testingPatient samplesType 4Whole-genome sequencingSubstantial numberEnvironmental specimensHAdVOutbreakUS Coast Guard AcademyPotential immunomodulatory effects of vitamin D in the prevention of severe coronavirus disease 2019: An ally for Latin America (Review)
Turrubiates-Hernández F, Sánchez-Zuno G, González-Estevez G, Hernández-Bello J, Macedo-Ojeda G, Muñoz-Valle J. Potential immunomodulatory effects of vitamin D in the prevention of severe coronavirus disease 2019: An ally for Latin America (Review). International Journal Of Molecular Medicine 2021, 47: 32. PMID: 33537824, PMCID: PMC7891829, DOI: 10.3892/ijmm.2021.4865.Peer-Reviewed Original ResearchMeSH KeywordsBone and BonesCOVID-19Dietary SupplementsHumansImmunologic FactorsLatin AmericaPrevalenceRenin-Angiotensin SystemRespiratory Tract InfectionsVitamin DVitamin D DeficiencyConceptsVitamin D deficiencyD deficiencyVitamin DPotential immunomodulatory effectsD recommendationsPrevention of COVID-19 complicationsPrevalence of vitamin D deficiencyImmunomodulatory effectsImmunomodulatory effect of vitamin DAcute respiratory distress syndromePoor prognosis of COVID-19Effects of vitamin DRespiratory distress syndromeVitamin D recommendationsNovel treatment optionsPrognosis of COVID-19Severe coronavirus diseaseGlobal health problemCOVID-19 complicationsDistress syndromePoor prognosisBone healthSevere acute respiratory syndrome coronavirus 2Treatment optionsAcute respiratory syndrome coronavirus 2
2020
COVID-19 in Great Britain: epidemiological and clinical characteristics of the first few hundred (FF100) cases: a descriptive case series and case control analysis
Boddington N, Charlett A, Elgohari S, Walker J, McDonald H, Byers C, Coughlan L, Vilaplana T, Whillock R, Sinnathamby M, Panagiotopoulos N, Letley L, MacDonald P, Vivancos R, Edeghere O, Shingleton J, Bennett E, Grint D, Strongman H, Mansfield K, Rentsch C, Minassian C, Douglas I, Mathur R, Peppa M, Cottrell S, McMenamin J, Zambon M, Ramsay M, Dabrera G, Saliba V, Bernal J. COVID-19 in Great Britain: epidemiological and clinical characteristics of the first few hundred (FF100) cases: a descriptive case series and case control analysis. Bulletin Of The World Health Organization 2020, 99: 178-189. PMID: 33716340, PMCID: PMC7941108, DOI: 10.2471/blt.20.265603.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAge DistributionAgedChildChild, PreschoolCOVID-19DyspneaFemaleHumansInfantMaleMiddle AgedRespiratory Tract InfectionsSARS-CoV-2TravelUnited KingdomYoung AdultConceptsProportion of COVID-19 casesPredictive value of symptomsTraining public health professionalsHealth-care seeking behaviorOccurrence of feverCase-control analysisCourse of diseaseSpecificity of symptomsShortness of breathPublic health professionalsProportion of childrenClinical presentationClinical characteristicsExposure to infectionRespiratory infectionsCases of coronavirus disease 2019Household contactsHealth professionalsBurden of COVID-19Predictive valueCase definitionCoronavirus disease 2019COVID-19 casesControl groupFever
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply